Recurrent ovarian cancer
Clinical trials for Recurrent ovarian cancer explained in plain language.
Never miss a new study
Get alerted when new Recurrent ovarian cancer trials appear
Sign up with your email to follow new studies for Recurrent ovarian cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail targets Hard-to-Treat ovarian and uterine cancers
Disease control OngoingThis early-phase trial tests an investigational drug called RP-6306 alongside standard chemotherapy (carboplatin and paclitaxel) in 6 women with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find a safe dose and check …
Matched conditions: RECURRENT OVARIAN CANCER
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug duo aims to stall ovarian Cancer's return
Disease control OngoingThis phase 2 trial is testing whether adding oregovomab (an antibody) to niraparib (a daily pill) can better control platinum-sensitive recurrent ovarian cancer. Ten women whose cancer came back after initial chemotherapy will receive both drugs for 12 weeks. The main goal is to …
Matched conditions: RECURRENT OVARIAN CANCER
Phase 2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can eye drops save sight during ovarian cancer treatment?
Symptom relief OngoingThis phase 2 trial tests whether different eye drops can prevent or reduce eye problems caused by the cancer drug mirvetuximab soravtansine in 100 people with recurrent ovarian cancer. Participants will receive the cancer drug along with either lubricating drops, steroid drops, o…
Matched conditions: RECURRENT OVARIAN CANCER
Phase 2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC